Please assess the completion status of the following clinical trial:

Trial Title: Anakinra as a Treatment for Hydradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1) Signed informed consent form with Confirmed diagnosis of hidradenitis suppurativa with moderate or severe disease activity~Exclusion Criteria:~1. Use of the following therapies:~   * Etanercept in the 4 weeks prior to the baseline visit (Day 1)~  * Adalimumab in the 8 weeks prior to the baseline visit (Day 1)~  * Infliximab in the 12 weeks prior to the baseline visit (Day 1)~  * Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1)~  * Leflunomide in the 4 weeks prior to the baseline visit (Day 1) • Thalidomide in the 4 weeks prior to the baseline visit (Day 1)~  * Cyclosporine in the 4 weeks prior to the baseline visit (Day 1)~  * I.V. immunoglobulin (I.V. Ig) in the 8 weeks prior to the baseline visit (Day 1)~  * 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1)~  * Colchicine, dapsone, mycophenolate mofetil \& systemic antibiotics in the 3 weeks prior to the baseline visit (Day 1)~  * Corticosteroids 20mg/day or \>0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (Day 1)~2. history of immunocompromise including HIV infection~3. positive Hep B surface antigen -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).